title: Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
abstract: Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market.
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D005060:Europe; D024841:Fluoroquinolones; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D000077266:Moxifloxacin; D011008:Pneumococcal Infections / Q000188:drug therapy; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D056737:Safety-Based Drug Withdrawals; D012852:Sinusitis / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin